secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001628280-26-032935
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen completes PALISADE-4 Phase 3 patient visits; topline data due Q2 2026
------------------------------------------------------------------------------

- Last patient completed randomized portion of Phase 3 trial for fasedienol acute treatment of social anxiety disorder.
- Topline results for PALISADE-4 expected in second quarter 2026.
- FDA has no comments on refined statistical analysis plan incorporating pre-dose SUDS baseline covariate.
- Open-label extension remains ongoing; fasedienol has FDA Fast Track designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026032935/0001628280-26-032935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026032935/vtgn-20260508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-032935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer